Lexicon Pharmaceuticals to Present Groundbreaking Research
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), based in The Woodlands, Texas, is excited to announce significant advancements in diabetes management research that will be shared at the 85th Scientific Sessions of the American Diabetes Association (ADA). This prestigious congress, scheduled from June 20 to June 23, is a pivotal event in the diabetes community, providing a platform for sharing new ideas and healthcare innovations.
Key Presentations on Sotagliflozin and Pilavapadin
The key highlight of Lexicon's presentations will be the oral discussion on the effects of sotagliflozin regarding hypoglycemia in individuals with type 1 diabetes. This session is set for June 22, and renowned expert, M. Belinda Hardin, PharmD, BCPS, will articulate the clinical efficacy data, categorized based on kidney function metrics.
Moreover, Lexicon will unveil topline findings from their PROGRESS Phase 2b study focusing on pilavapadin (LX9211), a promising candidate for treating diabetic peripheral neuropathic pain in adults. This work is critical, as diabetes often leads to debilitating neuropathic conditions that severely impact patients' quality of life.
Highlighting the Importance of Hypoglycemia Prevention
Hypoglycemia presents a serious concern for those living with type 1 diabetes. The ADA has underscored the necessity of proactive management approaches to mitigate such risks. As stated in their recent clinical update, healthcare professionals must prioritize strategies to prevent instances of hypoglycemia.
During the conference, Dr. Hardin will present findings through a session titled “Interventions to Prevent Hypoglycemia: Bench to Bedside,” highlighting the importance of these strategies and fostering a rich dialogue among attendees and experts in the field.
Prominent Presentation Details
The oral presentation concerning sotagliflozin will be held on June 22 from 4:00 to 4:15 p.m. CT, where Dr. Hardin will elaborate on how sotagliflozin reduces the risk of critical hypoglycemic events across various kidney function demographics. This presentation is anticipated to be insightful for healthcare professionals as they develop comprehensive treatment plans for their patients.
Additionally, at the same venue, Lexicon will share details regarding pilavapadin, focusing on its innovative non-opioid approach to treat neuropathic pain, which can be challenging to manage effectively. This presentation is scheduled for June 22 from 12:30 to 1:30 p.m. CT.
The Science Behind Sotagliflozin
Sotagliflozin represents a groundbreaking therapeutic option discovered through Lexicon's advanced gene science methodologies. As an integral molecule, it inhibits sodium-glucose cotransporters SGLT1 and SGLT2, which play crucial roles in glucose management within the body. The extensive research surrounding this compound has involved nearly 20,000 patients across diverse therapeutic areas, emphasizing its potential in managing diabetes effectively.
Overview of the PROGRESS Study
The comprehensive PROGRESS study commenced in late 2023, engaging 496 adult participants diagnosed with diabetes and suffering from moderate to severe diabetic peripheral neuropathic pain. This study aims to assess the efficacy of pilavapadin by measuring the changes in pain levels over eight weeks while allowing participants to maintain current treatments, thus ensuring the findings align with the realistic scenarios faced in clinical practice.
Understanding Diabetic Peripheral Neuropathic Pain (DPNP)
DPNP is a prevalent and painful complication associated with diabetes, affecting millions of individuals. Symptoms can range from burning sensations to numbness, leading to considerable distress and impairment. Approximately 9 million people in the U.S. are currently battling this chronic condition, underscoring the urgency for effective therapeutic interventions.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals stands at the forefront of biopharmaceutical innovations. Their mission is dedicated to pioneering new medicines aimed at transforming the lives of patients. The company’s Genome5000™ program is approximately analyzing nearly 5,000 genes, leading to the identification of numerous therapeutic targets across various diseases. This rigorous research and development effort showcases Lexicon's commitment to advancing healthcare solutions and improving outcomes for patients dealing with significant health challenges.
Frequently Asked Questions
What is the main focus of Lexicon's presentation at the ADA?
Lexicon will present data on sotagliflozin's effects on hypoglycemia prevention in type 1 diabetes and share findings from the PROGRESS study regarding pilavapadin for neuropathic pain.
When will Lexicon's presentations take place?
The presentations are scheduled for June 22, with sotagliflozin's discussion from 4:00 to 4:15 p.m. CT, and the pilavapadin presentation from 12:30 to 1:30 p.m. CT.
Why is hypoglycemia management significant for diabetes patients?
Hypoglycemia can lead to severe health risks for diabetes patients, making effective management essential for their overall health and well-being.
What is pilavapadin and its relevance in diabetes treatment?
Pilavapadin is an oral, non-opioid drug being evaluated for its effectiveness in treating diabetic peripheral neuropathic pain, helping to manage complications associated with diabetes.
How many patients are enrolled in the PROGRESS study?
The PROGRESS study involves 496 adult patients diagnosed with either type 1 or type 2 diabetes and experiencing moderate to severe diabetic peripheral neuropathic pain.
